![Ellen Feigal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ellen Feigal
Directeur/Membre du Conseil chez
XENCOR, INC.
Fortune : 307 883 $ au 30/09/2026
Profil
Dr. Ellen G.
Feigal, MD, is an Independent Director at NextCure, Inc., an Independent Director at Xencor, Inc. and a Partner & Head-Biologics Practice at NDA Partners LLC.
She is on the Board of Directors at Prescient Therapeutics Ltd., NextCure, Inc., Xencor, Inc. and Foundation For Cell & Gene Medicine.
Dr. Feigal was previously employed as a Vice President-Research & Development by California Institute for Regenerative Medicine, an Executive Medical Director-Global Development by Amgen, Inc., a Chief Medical Officer by INSYS Therapeutics, Inc., a Director-Medical Devices & Imaging by Critical Path Institute, a Director-American Course on Drug Development by University of California, a Vice President-Clinical Sciences by Translational Genomics Research Institute, and a Deputy Director-Cancer Treatment Division by National Cancer Institute.
She also served on the board at The University of California, San Francisco.
She received her undergraduate degree from the University of Minnesota, a graduate degree from the University of California, Berkeley, a doctorate degree from the University of California, Davis and a doctorate degree from Stanford University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XENCOR, INC. 0,02 % | 18/06/2026 | 12 340 ( 0,02 % ) | 307 883 $ | 30/09/2026 |
NEXTCURE, INC. -.--% | 18/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| 30/06/2025 | 0 ( -.--% ) | - $ | 30/09/2026 |
Postes actifs de Ellen Feigal
| Sociétés | Poste | Début |
|---|---|---|
| NEXTCURE, INC. | Directeur/Membre du Conseil | 01/10/2021 |
| PRESCIENT THERAPEUTICS LIMITED | Directeur/Membre du Conseil | 15/05/2023 |
| XENCOR, INC. | Directeur/Membre du Conseil | 01/11/2018 |
NDA Partners LLC
 NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services | Corporate Officer/Principal | 01/12/2014 |
Foundation For Cell & Gene Medicine
 Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ellen Feigal
| Sociétés | Poste | Fin |
|---|---|---|
California Institute for Regenerative Medicine
 California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services | Directeur Technique/Scientifique/R&D | 01/12/2014 |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2011 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
| INSYS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2008 |
| ░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Ellen Feigal
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
88
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Prescient Therapeutics Ltd.
 Prescient Therapeutics Ltd. BiotechnologyHealth Technology Operates as a a clinical stage oncology company | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services | Government |
NDA Partners LLC
NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services | Commercial Services |
Translational Genomics Research Institute
 Translational Genomics Research Institute Miscellaneous Commercial ServicesCommercial Services Operates as a cancer, neurological disorders and infectious disease medical research institute | Commercial Services |
Critical Path Institute
 Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Provides medical drug and product development review process | Commercial Services |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty pharmaceutical company | Health Technology |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NextCure, Inc.
 NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
Foundation For Cell & Gene Medicine
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. |
